Charles River Laboratories’ first quarter drew a highly positive market response, with results driven by stronger-than-expected demand in its Drug Safety Assessment (DSA) segment and signs of stabilization across client groups. Management credited improved bookings and a net book-to-bill ratio above 1x for the DSA segment, noting this was the first such result in over two years. CEO Jim Foster highlighted, “We were pleased to see the DSA net book-to-bill return to just above 1x for the first time in over 2 years due to improved quarterly bookings.” Cost savings from restructuring initiatives also supported margins, offsetting revenue declines from lower commercial activity in parts of the business.

Is now the time to buy CRL? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Charles River Laboratories’s Q1 Earnings Call

• Max Smock (William Blair) asked if recent FDA messaging will drive immediate changes in study designs. CEO Jim Foster responded that the transition to NAMs will be gradual, requiring significant validation and ongoing client adaptation.
• Eric Coldwell (Baird) inquired about Charles River’s leadership in NAMs and willingness for further M&A. Foster highlighted proprietary data, strategic investments, and openness to acquiring validated alternative technologies.
• Ann Hynes (Mizuho Securities) questioned long-term growth rates post-FDA changes. Foster said the company will refresh its long-term growth targets after further assessment, while CFO Flavia Pease noted stable pricing aided by study mix.
• Michael Ryskin (Bank of America) probed whether the first quarter’s DSA bookings strength might represent a pull-forward. Foster characterized the quick-start bookings as a likely one-off driven by available capacity, not a sustained trend.
• Patrick Donnelly (Citi) asked if the improved DSA book-to-bill ratio can be maintained. Foster expressed optimism but remained cautious, stating that “several quarters” of similar performance would be needed to confirm a shift.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) sustainability of improved DSA bookings and whether book-to-bill ratios remain above 1x, (2) progress in NAMs commercialization and regulatory acceptance as the FDA pilot expands, and (3) the impact of NIH funding decisions and biotech capital flows on segment revenue. Execution on cost-saving initiatives and updates from the ongoing strategic review will also be key signals.

Charles River Laboratories currently trades at $157.12, up from $115.33 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.